

## List of figures

Fig. No	Title	Page. No
<b>Review of literature</b>		
2.1	Bone remodelling by balanced functioning of osteoblasts (formation) and osteoclasts (resorption)	21
2.2	Optimal treatment of osteoporosis in postmenopausal women	25
<b>PART-I</b>	<b>Chapter 1</b>	
1.1	General chemical structure of (A) Markers of F147 (B) Medicarpin	46
1.2.1	MS/MS spectra of K040 and K051	54
1.2.2	MS/MS spectra of K052, K053 and K054	55
1.2.3	MS/MS spectra of K080, K095 and K080	56
1.2.4	MS/MS spectra of IS(-) and IS(+)	57
1.3.1	LC-MS/MS chromatogram of markers K040, K053, K051 and K095	62
1.3.2	LC-MS/MS chromatogram of markers C1, C2, K052, K054 and K080	63
1.3.3	LC-MS/MS chromatogram of markers K098, C3, C4, C5, C6, C10 and C7	64
1.3.4	LC-MS/MS chromatogram of markers C8, C9, C11, C12, C13, C14 and IS	65
1.4	RDA fragmentation of isoflavone	68
1.5	Loss of carbonyl groups from (A) isoflavone and (B) flavone	69
1.6	Scheme for the fragmentation of cladrin in ESI (+)-MS/MS	73
1.7.1	MS/MS spectra of K040 and K051 in positive mode	74
1.7.2	MS/MS spectra of K052, K053 and K054 in positive mode	75
1.7.3	MS/MS spectra of K080, K095 and K098 in positive mode	76
1.8.1	MS/MS spectra of C1; (A)-Normal view, (B)-Enlarged view	77
1.8.2	MS/MS spectra of C2; (A)-Normal view, (B)-Enlarged view	78
1.9.1	MS/MS spectra of C3, C4 and C5; (A)-Normal view, (B)-Enlarged view	79
1.9.2	MS/MS spectra of C6 and C7; (A)-Normal view, (B)-Enlarged view	80
1.10.1	MS/MS spectra of C8 and C9; (A)-Normal view, (B)-Enlarged view	82
1.10.2	MS/MS spectra of C10 and C11; (A) Normal view, (B) Enlarged view	83
1.11	MS/MS spectra of C12/C13; (A) Normal view, (B) Enlarged view	84
1.12	MS/MS spectra of C14; (A) Normal view, (B) Enlarged view	85

<b>Fig.No</b>	<b>Title</b>	<b>Page No</b>
<b>Chapter 2</b>		
2.1.1	LC-MS/MS chromatogram of blank plasma for MRM of markers K040, K051 and K053	101
2.1.2	LC-MS/MS chromatogram of blank plasma for MRM of markers K080, K098 and K095	102
2.1.3	LC-MS/MS chromatogram of blank plasma for MRM of IS in negative and positive mode	102
2.2.1	LC-MS/MS chromatogram of markers K040, K095, K051, K053 and K080 spiked in rat plasma	103
2.2.2	LC-MS/MS chromatogram of marker K098 and IS spiked in rat plasma	104
2.3.1	Graph of freeze thaw stability of markers K040, K051 and K053	108
2.3.2	Graph of freeze thaw stability of markers K080, K095 and K098	109
<b>Chapter-3</b>		
3.1.1	LC-MS/MS chromatogram of markers K040 and K095 after i.v. dosing of F147 in rats	115
3.1.2	LC-MS/MS chromatogram of markers K053, K051, K080 and K098 after i.v. dosing of F147 in rats	116
3.2.1	Plasma c-t profile of markers K040, K051 and K053 after i.v.dosing of F147 in rats	117
3.2.2	Plasma c-t profile of markers K080, K095 and K098 after i.v. dosing of F147 in rats	118
3.3.1	LC-MS/MS chromatogram of markers K040, K095, K051 and K053 after oral dosing of F147 in rats	121
3.3.2	LC-MS/MS chromatogram of markers K080 and K098 after oral dosing of F147 in rats	122
3.4.1	Plasma c-t profile of marker K040 after oral dosing of F147 in rats	122
3.4.2	Plasma c-t profile of markers K051, K053 and K080 after oral dosing of F147 in rats	123
3.4.3	Plasma c-t profile of markers K095 and K098 after oral dosing of F147 in rats	124

<b>Fig.No</b>	<b>Title</b>	<b>Page No</b>
<b>Chapter-4</b>		
4.1	Structures of (A) K095, (B) S006-1709, (C) K054, (D) 7-hydroxy isoflavone and (E) Biochanin	128
4.2.1	MS/MS spectra of (A) Medicarpin and (B) Cladrin	137
4.2.2	MS/MS spectra of (A) 7-hydroxy isoflavone and (B) S006-1709	138
4.2.3	MS/MS spectrum of Biochanin	139
4.3.1	LC-MS/MS chromatogram of blank rat plasma for MRM of (A)K095 and IS (B) IS	140
4.3.2	LC-MS/MS chromatogram of rat plasma spiked with (A)K095 and IS (B) IS	140
4.4.1	LC-MS/MS chromatogram of blank rat plasma for MRM of (A) K054 and (B) IS	141
4.4.2	LC-MS/MS chromatogram of rat plasma spiked with (A) K054 and (B) IS	141
4.5.1	LC-MS/MS chromatogram of blank rat plasma for MRM of (A) S006-1709 and (B) IS	142
4.5.2	LC-MS/MS chromatogram of rat plasma spiked with (A) S006-1709 and (B) IS	142
4.6.1	Graph of freeze thaw stability of K095 and K054S006-1709 in rat plasma	146
4.6.2	Graph of freeze thaw stability of S006-1709 in rat plasma	147
<b>Chapter-5</b>		
5.1.1	LC-MS/MS chromatogram of K095 after i.v. dosing in rats	151
5.1.2	LC-MS/MS chromatogram of K095 after oral dosing in rats	151
5.2	Plasma c-t profile of K095 after (A) i.v. and (B) oral dosing in rats	152
5.3.1	LC-MS/MS chromatogram of K054 after i.v. dosing in rats	154
5.3.2	LC-MS/MS chromatogram of K054 after oral dosing in rats	154
5.4	Plasma c-t profile of K054 after (A) i.v. and (B) oral dosing in rats	155
5.5.1	LC-MS/MS chromatogram of S006-1709 after i.v. dosing in rats	156
5.5.2	LC-MS/MS chromatogram of S006-1709 after oral dosing in rats	157
5.6	Plasma c-t profile of S006-1709 after (A) i.v. and (B) oral dosing in rats	158

<b>Fig.No</b>	<b>Title</b>	<b>Page No</b>
<b>Chapter-6</b>		
6.1	The hypothetical two-compartment model describing the basis of charcoal adsorption assay for protein binding estimation.	162
6.2.1	Percentage drug remaining versus time profile of K054	164
6.2.2	Percentage drug remaining versus time profile of K095	164
6.2.3	Percentage drug remaining versus time profile of S006-1709	165
6.3	Structures of (A) K095, S006-1709; (B) K054; (C) Quercetin	165
<b>Chapter-7</b>		
7.1	Structures of pterocarpan and isoflavones	173
7.2.1	Degradation profile of K095 in rat liver microsomes	173
7.2.2	Degradation profile of K054 in rat liver microsomes	174
7.2.3	Degradation profile of S006-1709 in rat liver microsomes	174
<b>PART-II</b>	<b>Chapter—1</b>	
1.1	Chemical structure of (A) Quercetin-6-C- $\beta$ -D-glucopyranoside (K012), (B) (2S,3S)-(+)-3'4'5,7-tetrahydroxydihydroflavonol-6-C- $\beta$ -D-glucopyranoside (K058), (C) Naringenin-6-C- $\beta$ -D-glucopyranoside (K068), (D) (2S,3S)-(+)-4'5,7-trihydroxydihydroflavonol-6-C- $\beta$ -D-glucopyranoside (K100) and (D) Ononin	177
1.2	HPLC-PDA chromatogram of (A) reference standards at 290nm, (B) reference standards at 260nm overlaid on blank. (1) K058 (2) K100 (3) K068 and (4) K012	182
1.3	Overlay of HPLC-PDA chromatogram of 914/F009 and 914/C008, (A) at 290nm (B) at 260nm. (1) K058 (2) K100 (3) K068 and (4) K012	185
1.4	Overlay of HPLC-PDA chromatogram of BFT, AFT and EFT (A) at 290nm (B) at 260nm. (1) K058 (2) K100 (3) K068 and (4) K012	186
<b>Chapter-2</b>		
2.1	Structures of (A) K058, (B) Ononin	188
2.2.1	MS/MS spectrum of K058	192
2.2.2	MS/MS spectrum of Ononin	193

<b>Fig.No</b>	<b>Title</b>	<b>Page No</b>
2.3	LC-MS/MS chromatogram of blank plasma for MRM of (A) K058 (B) IS; rat plasma spiked with (C) K058 and (D) IS	194
2.4	Graph of freeze thaw stability of K058 in rat plasma	196

### **Chapter-3**

3.1.1	LC-MS/MS chromatogram of K058 after i.v. oral dosing in rats	200
3.1.2	LC-MS/MS chromatogram of K058 after oral dosing in rats	201
3.2	Plasma c-t profile of K058 after (A) i.v. and (B) oral dosing in rats	201

## List of Tables

Table. No	Title	Pg. No
<b>Review of Literature</b>		
2.1	Therapies for osteoporosis	24
2.2	Analysis of flavonoids in herbal products	29
<b>PART-I</b>		
<b>Chapter 1</b>		
1.1	Chemical structure of markers of F147	46
1.2	Preparation of analytical standards (AS) and quality controls (QC)	47
1.3	Gradient condition for LC-MS/MS method of F147	48
1.4	Mass spectrometric conditions of F147 markers	50
1.5	Validation data of F147 markers	59
1.6	Intra-day and inter-day accuracy and precision of F147 markers	60
1.7	Percentage content and relative peak area of makers and C1-C14 of F147	61
1.8	Comparison of relative content of compounds in F147	62
1.9	Guidelines for structural elucidation of isoflavones and flavones	67
1.10	RDA fragments for identification of substitutions in markers of F147	68
1.11	Fragments to distinguish isoflavones and flavones of markers of F147	69
1.12	Characteristic fragments for identification of 5-hydroxyl and 4'-methoxyl group	71
1.13	Characteristic fragments for identification of methoxyl groups in F147 markers	72
1.14	RDA fragments for identification of substitutions in compounds C1-C13 of F147	86
1.15	Fragments to distinguish isoflavones and flavones in compounds C1-C13 of F147	87
1.16	Characteristic fragments for identification of 5-hydroxyl and 4'-methoxyl group in compounds C1-C13 of F147	88
1.17	Characteristic fragments for identification of methoxyl groups in compounds C1-C13 of F147	89
1.18	Proposed structures for compounds C1-C14 of F147	90
<b>Chapter-2</b>		
2.1	Preparation of calibration standards (CS) and quality controls (QC)	96

<b>Table. No</b>	<b>Title</b>	<b>Pg. No</b>
2.2	Gradient condition for LC-MS/MS method of markers of F147	97
2.3	Mass spectrometric conditions for LC-MS/MS method of F147 markers	98
2.4	Validation parameters of F147 markers	104
2.5	Recovery and matrix effect of markers of F147	105
2.6	Intra-day and Inter-day accuracy and precision of F147 markers	106
2.7	Freeze thaw stability of markers of F147	107
2.8	Stability of markers of F147 in plasma and processed samples	110
<b>Chapter-3</b>		
3.1	Pharmacokinetic parameters of F147 markers after i.v. dosing in female S.D. rats	119
3.2	Pharmacokinetic parameters of F147 markers after oral dosing in female S.D. rats	125
<b>Chapter-4</b>		
4.1	Preparation of calibration standards (CS) and quality controls (QC) of K095	130
4.2	Preparation of calibration standards (CS) and quality controls (QC) of K054	131
4.3	Preparation of calibration standards (CS) and quality controls (QC) of S006-1709	132
4.4	Chromatographic conditions of K095, K054 and S006-1709	134
4.5	Mass spectrometric conditions of K095, K054 and S006-1709	135
4.6	Validation data of medicarpin, cladrin and S006-1709	143
4.7	Recovery of K095, K054, S006-1709, 7-hydroxy isoflavone and biochanin from rat plasma	144
4.8	Intra-day and Inter-day accuracy and precision of K095, K054 and S006-1709 in rat plasma	144
4.9	Freeze thaw stability of K095, K054 and S006-1709 in rat plasma	145
4.10	Stability of K095, K054 and S006-1709 at different conditions	146
<b>Chapter-5</b>		
5.1	Pharmacokinetic parameters of K095 after i.v. and oral dosing in female S.D. rats	152

<b>Table. No</b>	<b>Title</b>	<b>Pg. No</b>
5.2	Pharmacokinetic parameters of K054 after i.v. and oral dosing in female S.D. rats	155
5.3	Pharmacokinetic parameters of S006-1709 after i.v. and oral dosing in female S.D. rats	158
<b>Chapter-7</b>		
7.1	HPLC-PDA conditions for K095, K054 and S006-1709	171
7.2	Metabolic stability of K095, K054 and S006-1709	173
<b>PART-II</b>		
<b>Chapter-1</b>		
1.1	Preparation of analytical standards (AS) and quality controls (QC)	179
1.2	Gradient condition for the separation of markers of 914	180
1.3	Dilution of herbal fractions	181
1.4	Validation data of HPLC-PDA method for 914 markers	183
1.5	Intra-day and inter-day accuracy and precision for markers of 914	184
1.6	Percentage content of markers in herbal fractions of <i>Ulmus wallichiana</i>	184
<b>Chapter-2</b>		
2.1	Preparation of calibration standards (CS) and quality controls (QC)	189
2.2	Intraday and Interday accuracy and precision of K058 in rat plasma	195
2.3	Freeze thaw stability of K058 in rat plasma	195
2.4	Stability of K058 at different conditions	196
2.5	Accuracy and precision values for dilution integrity	196
<b>Chapter-3</b>		
3.1	Pharmacokinetic parameters of K058 after i.v. and oral dosing in female S.D. rats	202